Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X:
“New ASCO Guidelines: Thyroid Cancer (2026)
Not “which drug?”
- It’s now “which mutation?”
Differentiated (RAI-refractory)
- No mutation ━ Lenvatinib > Sorafenib
- Progression ━ Cabozantinib
Mutation
- RET ━ Selpercatinib
- NTRK ━ Larotrectinib
- BRAF ━ Dabrafenib + Trametinib
Anaplastic thyroid cancer (ATC)
BRAF V600E ━ Dabrafenib + Trametinib = STANDARD
- No mutation ━
- Lenvatinib ± IO / Ipi+Nivo
Medullary thyroid cancer (MTC)
- RET+ ━ Selpercatinib
- RET WT ━ Cabozantinib / Vandetanib
What’s changed?
- Targeted therapy moves upfront
- Immunotherapy mostly out
- Chemo = last line
Takeaway:
- Test first. Treat later.
Save this before your next thyroid OPD.”
Title: Systemic Treatment of Thyroid Cancer: ASCO Guideline
Authors: Nabil F. Saba, Nofisat Ismaila, Douglas Adkins, Nishant Agrawal, Neil Akhave, Erik S. Blomain, Maria E. Cabanillas, Amy Chen, Thomas J. Galloway, Guilherme Harada, Dapeng Li, Salem I. Noureldine, Joe Scharpf, Lova L. Sun, Mei Tang, Lori Wirth, Francis Worden, Dan P. Zandberg and Beth M. Beadle.
Other articles featuring Rishabh Jain on OncoDaily.
